Most Compact System for Early Stage Processes – The Eppendorf DASbox Mini Bioreactor System, with its small working volume, compact design, as well as advanced control and information management options is ideal for research and early development processes.

Claire Skentelbery, well known and connected in the European biotech community, will be the new Director General of EuropaBio. She will join the EuropaBio team at the end of November.

Melanie Leveridge takes over the lead of the European Laboratory Research & Innovation Group (ELRIG) UK to drive further collaboration between academia and biopharma industry.

CDMO Continuous growth and diversification of the biotechnology market for pharmaceutical production have been recorded in the past years. It is expected that both trends, growth and diversification from blockbusters towards niche products, will continue. What requirements are derived from customers’ point of view and what are the advantages of Richter-Helm as a successful CDMO to fulfil such needs?

IP – In a recent decision (Royalty vs. DPMA; C-650/17), the European Court of Justice (ECJ) has shed some light on the conditions under which a supplementary protection certificate (SPC) may be granted. It has thus ended discussions that had arisen following earlier somewhat elusive ECJ-decisions. Whether this will be the last word to be heard on the topic remains to be seen.

Japanese CDMO Minaris Regenerative Medicine Co. Ltd  will invest US$64.5m to expand its facilities in Europe and Asia.

Lead investor Novo Growth has led a €22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein.

Growing sector – growing guide: The 22nd edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.

HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq.
 

In March 2021, Dr Jane Robertson will take over the position of Chief Medical Officer at Redx Pharma Plc in Alderley Park.